Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ChromaDex Corporation before investing.

In this article, we go over a few key elements for understanding ChromaDex Corporation’s stock price such as:

• ChromaDex Corporation’s current stock price and volume
• Why ChromaDex Corporation’s stock price changed recently
• Upgrades and downgrades for CDXC from analysts
• CDXC’s stock price momentum as measured by its relative strength

About ChromaDex Corporation (CDXC)

Before we jump into ChromaDex Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Want to learn more about ChromaDex Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ChromaDex Corporation.

ChromaDex Corporation’s Stock Price as of Market Close

As of March 06, 2025, 4:00 PM, CST, ChromaDex Corporation’s stock price was $7.690.

ChromaDex Corporation is down 10.06% from its previous closing price of $8.550.

During the last market session, ChromaDex Corporation’s stock traded between $7.550 and $8.500. Currently, there are approximately 75.97 million shares outstanding for ChromaDex Corporation.

ChromaDex Corporation’s price-earnings (P/E) ratio is currently at 77.7, which is high compared to the Life Sciences Tools & Services industry median of 37.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

ChromaDex Corporation Stock Price History

ChromaDex Corporation’s (CDXC) price is currently up 36.35% so far this month.

During the month of March, ChromaDex Corporation’s stock price has reached a high of $9.180 and a low of $5.265.

Over the last year, ChromaDex Corporation has hit prices as high as $9.180 and as low as $1.570. Year to date, ChromaDex Corporation’s stock is up 44.96%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ChromaDex Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of March 05, 2025,, no analysts have changed their rating of ChromaDex Corporation’s stock over the last month.

Additionally, you'll want to evaluate ChromaDex Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ChromaDex Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

ChromaDex Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ChromaDex Corporation (CDXC) by visiting AAII Stock Evaluator.

Relative Price Strength of ChromaDex Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 05, 2025, ChromaDex Corporation has a weighted four-quarter relative price strength of 44.67%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how ChromaDex Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ChromaDex Corporation Stock Price: Bottom Line

As of March 6, 2025, ChromaDex Corporation’s stock price is $7.690, which is down 10.06% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ChromaDex Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.